Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Selinexor Data in Myeloma and Personal Experience

November 22nd 2018

Selinexor Dose, Efficacy, and Adverse Effects

November 22nd 2018

Emerging Therapies: SINE inhibitor & the STORM trial

November 22nd 2018

Monoclonal Antibody, Triplet Therapy & Transplant Ineligible

November 22nd 2018

Relapse Therapy: Incremental Change Versus Different Regimen

November 22nd 2018

Incidence of Relapse for Myeloma and Triggers to Switch

November 22nd 2018

Defining Progression and an Approach to Management

November 22nd 2018

The Challenges of Long-Term Therapy

November 22nd 2018

The Definition and Importance of Long-Term Therapy

November 22nd 2018

Role of Transplantation, Maintenance, and Early Versus Late Response

November 22nd 2018

Evolving Therapy for Myeloma, Initiating Treatment & Risk Stratification

November 22nd 2018

Dr. Parekh on Evolving Treatment Landscape in Myeloma

November 20th 2018

Samir Parekh, MBBS, associate professor of medicine, Hematology/Oncology, Mount Sinai Hospital, discusses the evolving treatment landscape in myeloma.

Expert Evaluates Evolving Options in Newly Diagnosed Myeloma

November 20th 2018

Ravi Vij, MD, discusses emerging treatment options for patients with newly diagnosed multiple myeloma.

Dr. Chari Discusses the Importance of the ARROW Trial in Myeloma

November 17th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the importance of the ARROW trial in multiple myeloma.

Dr. Silver Talks About Advances in Treatment of Hematological Cancers

November 17th 2018

Joel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.

Dr. Green on Treatment Regimens for Patients With Multiple Myeloma in Early Relapse

November 13th 2018

Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

Dr. Vij on Maintenance and Consolidation in Newly Diagnosed Multiple Myeloma

November 9th 2018

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the use of maintenance and consolidation in multiple myeloma.

Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in Myeloma

November 7th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses the FDA approval of elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma.

FDA Approves Elotuzumab Triplet for Myeloma

November 7th 2018

The FDA has approved elotuzumab for use in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.

Dr. Valent on Dose-Adjusted Carfilzomib in Myeloma

November 6th 2018

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses the recent FDA approval of dose-adjusted carfilzomib in patients with myeloma.